Current Treatment Options in Oncology

, Volume 8, Issue 3, pp 252–260

Induction Chemotherapy for Head and Neck Squamous Cell Carcinomas (SCCHN)

Authors

    • Department of Thoracic/Head and Neck Medical OncologyUniversity of Texas, M. D. Anderson Cancer Center
Head and Neck Cancer

DOI: 10.1007/s11864-007-0035-z

Cite this article as:
Kies, M.S. Curr. Treat. Options in Oncol. (2007) 8: 252. doi:10.1007/s11864-007-0035-z

Opinion statement

Induction chemotherapy for squamous cell carcinoma of the head and neck has long been known to be highly active with tumor responses observed in a high percentage of patients. More recent studies have added taxane to traditional platin and infusional fluorouracil regimens. Docetaxel, cisplatin and 5-fluorouracil (TPF) is presently studied in prospective controlled trials to better define the efficacy and potential toxicity of sequential treatment with TPF followed by concomitant chemoradiotherapy. We await the results of these trials before we accept induction chemotherapy as a standard treatment and to best identify the subgroups of patients who may be most likely to benefit from the approach.

Copyright information

© Current Science Inc. 2007